Why the study?
Does scAAV6-amiR155-PLBr improve Ca2+ uptake into the sarcoplasmic reticulum with a better safety profile compared to scAAV6-shPLBr in cultured neonatal rat cardiomyocytes?
Population
Cultured neonatal rat cardiomyocytes (CM) isolated from ventricular tissue of 1-3-day-old Wistar rat pups
Comparison
scAAV6-amiR155-PLBr vs scAAV6-shPLBr and control AAV vectors
Design
Preclinical
Follow-up
14 days
Key result
scAAV6-amiR155-PLBr enhanced the Ca2+ transport function of the cardiac SR PLB/SERCA2a system as efficiently as scAAV6-shPLBr while offering a superior safety profile by avoiding proinflammatory protein induction.
Authors
Loading...
Supports safer microRNA AAV vectors for heart failure calcium handling; leaves open translation to in vivo and human studies.
Does scAAV6-amiR155-PLBr improve Ca2+ uptake into the sarcoplasmic reticulum with a better safety profile compared to scAAV6-shPLBr in cultured neonatal rat cardiomyocytes?
Absolute Event Rate: 77% vs 85%
An artificial microRNA-based AAV vector targeting phospholamban provides comparable improvements in cardiomyocyte calcium handling as shRNA vectors but avoids the induction of proinflammatory STAT proteins, offering a safer gene therapy approach for heart failure.
Größl et al. (2014) studied Heart failure (in vitro model). scAAV6-amiR155-PLBr vs. scAAV6-shPLBr and control vectors was evaluated on Normalized Ca2+ transport activity at submicromolar free Ca2+ concentration (% of maximal value). scAAV6-amiR155-PLBr enhanced the Ca2+ transport function of the cardiac SR PLB/SERCA2a system as efficiently as scAAV6-shPLBr while offering a superior safety profile by avoiding proinflammatory protein induction.